Enjoy complimentary customisation on priority with our Enterprise License!
The global infection control market has the potential to grow by USD 29.49 billion during 2020-2024, and the market’s growth momentum will accelerate throughout the forecast period.
This report provides a detailed analysis of the market by geography (Asia, Europe, North America, and ROW) and type (therapeutic and non-therapeutic). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including 3M Co., Astellas Pharma Inc., Cantel Medical Corp., Ecolab Inc., Getinge AB, GlaxoSmithKline Plc, Merck & Co. Inc., Mylan NV, Pfizer Inc., and Sanofi.
Browse TOC and LoE with selected illustrations and example pages from infection control market report
The market is moderately fragmented, and the degree of fragmentation will increase during the forecast period. The players in the market are diversified and industry-specific in terms of their overall offerings. Established vendors are focusing on investing in R&D activities and integrating technological advances into their products to cater to a variety of customer segments. Mylan NV, Pfizer Inc., and Sanofi are a few of the major market participants. Although the accelerating growth momentum will offer immense growth opportunities, the concerns regarding the safety of reprocessed instruments will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market positions, this infection control market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this infection control market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading infection control companies, including:
For more insights on the market share of various regions Request for a FREE sample now!
North America was the largest market for infection control in 2019, and the region will continue to offer growth opportunities to market vendors during the forecast period. Pharmaceutical companies have increased investments in R&D activities for the production of improved drugs and also to adhere to stringent regulations for drug approval. These factors are contributing to the infection control market share growth.
Almost 33% of the market’s growth will originate from North America during the forecast period. The rising incidence of infectious diseases is increasing the demand for infection control interventions, creating significant business opportunities for many market vendors in the region. The US, Canada, and Mexico are the key markets for infection control in North America. Market growth in the region will be faster than the growth of the market in Asia and ROW.
Request for a FREE sample and Get more information on the market contribution of various types
The players in the therapeutics market segment offer anti-infectives, such as antibiotics, anti-fungal drugs, and anti-viral drugs, which are used for the prevention and treatment of various infectious diseases. Moreover, expenditure on infection control therapeutic regimen is also increasing owing to the rising prevalence of infections.
Moreover, market growth by the therapeutic segment will be faster than the growth of the market by the non-therapeutic segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the infection control market size.
The geriatric population is the most important sub-group that is majorly prone to contracting periodontal diseases compared with the adult population. Infectious diseases are the common cause of morbidity and mortality in geriatric patients. Infections such as pneumonia, urinary tract infection, and bacterial spectrum are often accompanied by the presence of serious complications in this sub-group. Therefore, the growing proportion of the geriatric population is increasing the need for immediate treatment with infection control therapeutics is increasing. For instance, in the US, the geriatric population is increasing at a rapid rate. These factors are contributing to the infection control market growth.
Request for a FREE sample now!
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.